Brainomix Unveils Revolutionary Stroke AI Technology at International Stroke Conference

Brainomix Launches an Innovative Stroke AI Platform

In a significant advancement for stroke treatment, Brainomix, a leader in AI medical imaging, introduced its new Brainomix 360 platform at the International Stroke Conference (ISC) in New Orleans. This state-of-the-art solution utilizes pioneering net water uptake (NWU) technology, which offers deeper insights into stroke injuries and aids in decision-making for treatment strategies.

Award-Winning Design and User Experience

The Brainomix 360 platform's usability has earned it the prestigious Red Dot Design Award, a recognition reserved for pioneering innovations. The award highlights the platform's excellence in usability, safety, and design, positioning it alongside acclaimed products from brands such as Apple, Sony, and Samsung. This new platform is designed to streamline workflows, allowing for faster and more informed decisions by healthcare professionals.

The Breakthrough Features of Brainomix 360

The most notable feature of this next-generation platform is the introduction of its net water uptake capability. This feature can analyze routine non-contrast CT (NCCT) scans automatically to provide valuable insights into brain injuries. Dr. George Harston, Chief Medical and Innovation Officer at Brainomix, emphasized the importance of NWU as an emerging imaging biomarker critical for treatment planning. This automated output of NWU provides clinicians with enhanced data to better understand stroke injuries, which is pivotal particularly in severe cases.

Research Presented at ISC

At the ISC, Brainomix presented five abstracts, three of which received the distinguished Paul Dudley White International Scholar Award, recognizing outstanding contributions in stroke research. The studies shed light on various aspects of the imaging model, including a national cost-effectiveness analysis indicating that widespread use of Brainomix 360 could improve thrombolysis and thrombectomy rates, thus enhancing patient outcomes. Further research explored the clinical impact of collateral circulation during inter-hospital transfers and innovative detection techniques for stroke mimics.

Enhancing Patient Outcomes with Precision Medicine

Brainomix’s pioneering technology is making strides towards precision medicine, particularly for stroke and lung fibrosis patients. The Brainomix 360 Stroke offers a fully automated imaging platform that allows for acute stroke assessments, ensuring that treatment decisions are both confident and timely across various healthcare settings. This technology aims to eliminate the uncertainty that often surrounds treatment decisions for stroke patients, leading to better prognoses and treatment options.

Conclusion

The introduction of the Brainomix 360 platform not only represents a technological leap in stroke treatment but also signifies a strong commitment to improving patient care through advanced imaging techniques. Brainomix continues to push the boundaries of medical imaging, ensuring that healthcare professionals are equipped with the best tools to deliver optimal care for stroke patients worldwide. To learn more about Brainomix and its innovative solutions, visit their official website.

For further inquiries, contact:
Jeff Wyrtzen, Chief Marketing Officer
T: +44 (0)1865 582730
Email: [email protected]

This initiative marks a pivotal moment in stroke management and underlines Brainomix’s leading role in the evolution of AI-driven medical imaging.